ArticleBMC cardiovascular disorders2026
End-stage valvular heart disease requiring heart transplantation: risk profile, surgical modifiers, and myocardial pathology.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEnd-stage valvular heart disease (VHD) constitutes a small but high-risk subset of heart transplant (HTx) recipients, and data describing their natural history and determinants of progression to HTx are limited. We aimed to characterize the clinical, genetic, surgical, and pathological substrates of patients undergoing HTx for end-stage VHD and to assess whether timely cardiac valvular surgery (CVS) mitigates progression to end-stage heart failure.
methodsWe retrospectively screened 961 consecutive recipients who underwent HTx for end-stage heart failure between January 2012 and December 2023. Patients with non-ischemic end-stage VHD due to a primary aortic valve lesion were identified by echocardiography and further adjudicated using cardiac magnetic resonance and explant pathology. After excluding ischemic and non-valvular cardiomyopathies and other predefined conditions, 45 patients constituted the final cohort.
resultsOf the 45 recipients, 78% had undergone prior CVS. CVS performed before heart failure or malignant ventricular arrhythmia was associated with a longer interval from symptom onset to HTx. In contrast, genetic variants were associated with earlier disease onset but did not significantly shorten the progression interval to HTx. Among 27 patients with prosthetic valves, 22 (77%) had structurally and hemodynamically preserved prostheses at the time of HTx, indicating that terminal HF predominantly reflected advanced myocardial disease rather than prosthetic failure. Explanted hearts consistently demonstrated extensive replacement fibrosis, and patients with malignant ventricular arrhythmias exhibited more prominent adipose replacement.
conclusionsAmong patients transplanted for end-stage VHD, valve intervention performed prior to major clinical decompensation was associated with longer time intervals to HTx within this transplanted cohort. Most prosthetic valves showed preserved function at the time of HTx, supporting the concept that terminal heart failure in this setting often reflects advanced myocardial remodeling rather than prosthetic valve failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.